Overview

ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and the dose-response of ASP1517 in the treatment of anemia in non-dialysis Chronic Kidney Disease (CKD) patients when ASP1517 is applied intermittently.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc